Delivery Order SPE2DB22D2206-SPE2DB25FJV96
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 120ml quantity, valued at $1,378.38. The contract, executed on August 19, 2025, represents a firm fixed-price delivery order with an ultimate completion date of August 20, 2025. This award carries no set-aside designation, indicating that it was competitively awarded among eligible vendors. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $3,016.29. This is a firm fixed-price delivery order with an ultimate completion date of August 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $12,175.85 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity. This competitively awarded, firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this delivery order falls under...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) with a ceiling value of $1,731.16. This competitively awarded, non-set-aside contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,363.38. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The contract involved no set-aside designation and was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity, with a ceiling value of $2,110.28. This is a firm fixed price delivery order under a non-set-aside competitive award. The order is scheduled for completion by September 3, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract action, this...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJV96Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL) on September 10, 2025, with a ceiling value of $1,953.55. This is a firm fixed-price delivery order with no set-aside designation, indicating that the award was competitively procured. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor that serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the DLA Medical Supply Chain. The company's DLA indefinite delivery vehicle enables the supply of a comprehensive range of pharmaceutical products, medical supplies, vaccines, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare programs worldwide. The current delivery order for Quillivant XR—a methylphenidate-based medication used in attention deficit disorder treatment—reflects AmerisourceBergen's continued role as a key pharmaceutical supplier to federal defense healthcare operations, with an ultimate completion date of September 11, 2025.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/10/25 |